Authors
Theresa Spivey, Achim Jungbluth, Rene Serrette, Ting Zhou, Ozgur Can Eren, Jeeyeon Baik, Katherine Lopez, Mikhail Roshal, Ahmet Dogan, Alexander Chan
Published in
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Pages 101119. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
Distinguishing classic Hodgkin lymphoma (CHL) from anaplastic large cell lymphoma (ALCL) can be diagnostically challenging, particularly in cases where lineage-defining markers are diminished or absent. Both entities are CD30-positive lymphomas and may share overlapping morphologic features, including atypical cytology and disrupted immunophenotypic expression. While B-cell markers such as PAX5, OCT2, and BOB1 are used to support B-cell lineage in CHL, their inconsistent expression can limit diagnostic confidence. In this study, we evaluated the performance of CD40 immunohistochemistry (IHC) in a cohort of CD30-positive lymphomas. CD40, a receptor involved in B-cell activation and differentiation, has been previously reported in Hodgkin/Reed-Sternberg cells, but its diagnostic utility in this setting has not been comprehensively assessed in clinical practice or in this differential. Our findings show that CD40 IHC demonstrates 98.6% sensitivity and 100% specificity for CHL, including in diagnostically ambiguous cases such as PAX5-negative CHL and ALK-negative ALCL with a null phenotype. Notably, CD40 was consistently negative in all ALCL cases, including those requiring a clinicopathologic consensus diagnosis, underscoring its potential as a reliable marker of B-cell lineage. Although background staining in histiocytes and dendritic cells may complicate interpretation, careful morphologic correlation helps mitigate this issue. These results support the inclusion of CD40 into diagnostic panels for CD30-positive lymphomas with unclear lineage differentiation. Further comparative studies may help define its role alongside other B-cell markers and expand its utility across a broader range of lymphoid neoplasms.
PMID:
43051594
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0